作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家+企业家+投资家"大会圆满召开！ 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 (按首字母排序,排名不分先后，嘉宾单位或头衔为参 ...

Core Viewpoint - Solena Materials, a UK-based synthetic biology company, has raised $6.7 million in seed funding to scale the production of sustainable high-performance textile fibers made from novel protein fibers [1][2]. Group 1: Company Overview - Solena was founded in 2022 and previously secured €3.6 million in seed funding from Insempra [2]. - The company utilizes artificial intelligence to custom design protein fibers at the molecular level, optimizing characteristics such as appearance, feel, and tensile strength [2][3]. - Solena's technology represents a paradigm shift in protein fiber design, allowing for the creation of fibers that do not currently exist in nature [2][3]. Group 2: Technology and Production - The company’s approach involves designing proteins from scratch, making the production process simpler, more cost-effective, and highly scalable compared to traditional methods [2]. - Solena plans to relocate to a larger facility at the I-HUB building in Imperial College London to enhance collaboration with renowned fashion brands and increase production capacity [2]. Group 3: Industry Impact - The innovative technology of Solena is seen as a model for accelerating material discovery, combining computational design with rapid evaluation of fiber morphology [3]. - The protein-based fibers developed by Solena aim to replace petrochemical-derived materials, offering biodegradable and functional alternatives for consumers and industries [3].

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家+企业家+投资家"大会圆满召开！ 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 (按首字母排序,排名不分先后，嘉宾单位或头衔为参 ...

Core Viewpoint - JiaLian Technology is a high-tech enterprise engaged in the research, production, and sales of plastic products, biodegradable products, and plant fiber products, with a focus on expanding its global market presence and addressing challenges related to production capacity and financial costs [1]. Performance Overview - In 2024, the company achieved a total operating revenue of 2.326 billion yuan, an increase of 35.16% year-on-year; net profit attributable to shareholders was 57 million yuan, up 25.68% year-on-year; however, the net profit excluding non-recurring gains and losses decreased by 29.91% to 12.53 million yuan [2]. - In Q1 2025, the company reported an operating revenue of 506 million yuan, a slight increase of 1.29% year-on-year; net profit attributable to shareholders was -24.96 million yuan, a decline of 157.54% year-on-year; the net profit excluding non-recurring gains and losses was -25.20 million yuan, down 355.50% year-on-year [2]. Reasons for Performance Decline - The decline in performance is attributed to several factors: the expansion of production lines in 2024 led to lower capacity utilization rates as subsidiaries were in the initial production phase, resulting in increased manufacturing and management costs; additionally, interest expenses from unconverted convertible bonds contributed to higher financial costs [3]. Impact of Tariff Policies - The uncertainty surrounding U.S. tariff policies has prompted some customers to resume shipments based on inventory levels, leading to a gradual recovery in overseas sales. The company is actively monitoring U.S. tariff developments and maintaining close communication with customers to respond to potential geopolitical changes [4]. Future Overseas Market Development - The company's globalization strategy includes acquiring a U.S. subsidiary and investing in a production base in Thailand, along with establishing localized sales teams in multiple countries. This strategy enhances the company's international competitiveness and service capabilities, allowing for more flexible responses to global macroeconomic fluctuations and changes in trade policies [5]. Construction and Capacity Planning of Thailand Factory - The first phase of the factory in Thailand, covering 100,000 square meters, has been completed and is now in production. Orders are gradually being transferred for production and shipment, with the capacity expected to meet market demand as new products are introduced [6]. Outlook for Domestic Sales - With rising market demand due to increasing temperatures, the company aims to provide high-quality products and services in the food and beverage packaging sector. The focus is on continuous product development and customized solutions, leveraging years of technical expertise and collaboration with customers to enhance core competitiveness and profitability [7].

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文来源于锦波生物，仅作生物材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月28日， 山西锦波生物医药股份有限公司 （以下简称"锦波生物"）与 深圳湾实验室 正式签署合作协议，共建 深圳湾实验室-锦波生物基新材料联合研 究中心 。 锦波生物董事长杨霞 与 实验室主任颜宁 共同出席签约仪式，并就深化基础研究、推动产学研协同创新等议题展开战略对话。 图源 锦波生物 欢迎添加小编微信，加入 合成生物/生物制造/新材料 交流群 添加微信请备注： 姓名+公司+职务 ● 总投资1亿元，年产2万吨竹粉生物基降解材料及产品项目 ● 营收192.2亿元！国恩股份：启动10万吨/年可降解材料PHB项目，筹划"A+H"股上市 ● 甲醇→生物基材料，肆芃科技联合天津工生所，推动"一碳生物制造"！ ● 海淀区国企旗下，山东20万吨/年生物柴油异构项目顺利中交！ 在签约仪式上，颜宁博士表示，实验室始终践行"顶天立地"的科研理念——"顶天"是追求世界级科学发现，"立地"是推动科研成果惠及民生。此次合作正 是这一理念的实践。杨霞董事长强调，联合实验室将构建" ...

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 合成生物，聚势苏州：2024中国合成生物学"科学家+企业家+投资家"大会圆满召开！ 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 (按首字母排序,排名不分先后，嘉宾单位或头衔为参加往期活动时信息,或有改变） 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 2023中国(苏州)合 ...

Core Viewpoint - The company is focusing on high-end, intelligent, and low-carbon transformation, emphasizing continuous technological research and development to enhance business capabilities and accelerate the conversion of research results [1]. Group 1: R&D Investment - The company plans to allocate a budget of over 31 million yuan for 12 new R&D projects, including the development of bio-based new materials and various technical processes [1]. - The total profit for 2024 is projected to be over 97 million yuan, raising questions about the return on investment for the R&D expenditure [1]. Group 2: Collaboration and Development - In 2021, the company co-founded Ningbo Huafu New Materials Technology Co., Ltd., investing 8 million yuan for a 26.667% stake, focusing on the R&D, production, and sales of furan-based bio-materials [2]. - The company has successfully completed the pilot test of the 2,5-furandicarboxylic acid (FDCA) pilot plant, marking a significant milestone in the industrialization of furan-based new materials [2]. - The project is entering a new phase with the commencement of the pilot plant installation, which is expected to accelerate the industrialization process of FDCA and its derivatives [2].

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家+企业家+投资家"大会圆满召开！ 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 (按首字母排序,排名不分先后，嘉宾单位或头衔为参 ...

Core Insights - The article highlights the growing attention and support for synthetic biology, biomanufacturing, and the bio-industry from various sectors including government, academia, and investment [2][4][24] - The upcoming third SynBio Suzhou conference is scheduled for August 1-2, 2025, focusing on topics such as agriculture, food, energy, medical aesthetics, pharmaceuticals, and commercialization of synthetic biology technologies [2][3][14] Event Details - The third SynBio Suzhou conference will take place at the Suzhou International Expo Center, coinciding with the seventh CMC-China Expo [3][14] - The event aims to gather scientists, entrepreneurs, and investors to discuss the future of synthetic biology and its applications [2][4] Previous Events - The 2023 China (Suzhou) Synthetic Biology Innovation Summit was successfully held, indicating a strong interest and engagement in the field [4][24] - The article mentions a series of past successful events that have contributed to the development of synthetic biology in China [24]

Core Viewpoint - The article highlights the financial performance of Kasei Biotech in Q1 2025, showcasing significant growth in revenue and net profit, primarily driven by the sales of long-chain dicarboxylic acids [2][4]. Financial Performance - Kasei Biotech reported a revenue of 776 million yuan in Q1 2025, representing a year-on-year increase of 13.3% [2][3]. - The net profit attributable to shareholders reached 137 million yuan, up 30.1% compared to the same period last year [2][3]. - The net profit after deducting non-recurring gains was 135 million yuan, reflecting a 31.4% increase year-on-year [2][3]. - Research and development expenses amounted to 60.55 million yuan, marking a 35.21% increase from the previous year [2][3]. Product and Market Insights - The growth in net profit is attributed to the increased sales volume and gross profit from the series of long-chain dicarboxylic acids [4]. - Long-chain dicarboxylic acids (LCDA) are gaining traction in various applications, including the production of high-performance materials and pharmaceuticals [5]. - Kasei Biotech is positioned as a leading global supplier of bio-manufactured long-chain dicarboxylic acids, capitalizing on the market shift from traditional chemical methods to more sustainable production [5]. Capacity and Future Outlook - Kasei Biotech has a production capacity of 115,000 tons per year for bio-manufactured long-chain dicarboxylic acids and other related products [7]. - The company has successfully ramped up production of new products, such as dodecanedioic acid, contributing to significant revenue growth [6].